Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers
Status:
Completed
Trial end date:
2018-12-28
Target enrollment:
Participant gender:
Summary
A single-center, open-Label, randomized, single-dose, two-period, two-sequence, crossover
study to assess the bioequivalence of test formulation entecavir tablets 1.0 mg with
reference formulation entecavir tablets (Baraclude®) 1.0 mg in healthy adult subjects under
fasting conditions.